NJH-395

N/A

Report date: 2025/10/19 20:00:06

Base Information

Drug NameNJH-395

Drug Alias NameNJH-395

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsToll like receptor 7 agonists

TargetsReceptor protein-tyrosine kinase erbB-2Toll like receptor 7

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItalySouth Korea +[4]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A